Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Up 7.9% in October

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) saw a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 3,670,000 shares, a growth of 7.9% from the October 15th total of 3,400,000 shares. Based on an average trading volume of 443,400 shares, the short-interest ratio is presently 8.3 days. Approximately 6.4% of the shares of the stock are short sold.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. US Bancorp DE purchased a new stake in Aldeyra Therapeutics during the 3rd quarter valued at about $30,000. SG Americas Securities LLC purchased a new stake in shares of Aldeyra Therapeutics during the second quarter valued at approximately $38,000. Paloma Partners Management Co bought a new position in shares of Aldeyra Therapeutics in the third quarter worth approximately $62,000. Diversified Trust Co purchased a new position in shares of Aldeyra Therapeutics in the second quarter worth $41,000. Finally, King Wealth Management Group raised its stake in shares of Aldeyra Therapeutics by 24.5% during the third quarter. King Wealth Management Group now owns 13,700 shares of the biotechnology company’s stock valued at $74,000 after acquiring an additional 2,700 shares during the last quarter. Hedge funds and other institutional investors own 59.71% of the company’s stock.

Aldeyra Therapeutics Trading Down 1.4 %

Shares of ALDX opened at $4.21 on Monday. Aldeyra Therapeutics has a 1 year low of $2.43 and a 1 year high of $6.55. The stock has a 50 day simple moving average of $5.45 and a two-hundred day simple moving average of $4.60. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.18.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.25). On average, equities analysts anticipate that Aldeyra Therapeutics will post -0.89 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Aldeyra Therapeutics in a research report on Friday, August 9th.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-?B, inflammasomes, and Scavenger Receptor A.